Cytosorbents Corp (CTSO) stock
CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$5.57+1.05 (+23.12%)
Close on Nov 18, 2026Market cap $349.72MP/E –Yield –
Cytosorbents gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Cytosorbents's gross profit for the twelve months ending Sep 30, 2026 was $27.31M, up 5.3% year over year. For fiscal 2025 it was $26.49M, up 6.4% from the year before. Over ten years it grew 26.2% a year on average. The highest annual figure on record is $32.12M in fiscal 2021.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.49M | +6.4% |
| FY2024 | Dec 31, 2024 | $24.89M | +13.4% |
| FY2023 | Dec 31, 2023 | $21.95M | +5.9% |
| FY2022 | Dec 31, 2022 | $20.73M | -35.4% |
| FY2021 | Dec 31, 2021 | $32.12M | +7.2% |
| FY2020 | Dec 31, 2020 | $29.95M | +70.3% |
| FY2019 | Dec 31, 2019 | $17.59M | +17.1% |
| FY2018 | Dec 31, 2018 | $15.01M | +55.9% |
| FY2017 | Dec 31, 2017 | $9.63M | +72.8% |
| FY2016 | Dec 31, 2016 | $5.57M | +116.1% |
| FY2015 | Dec 31, 2015 | $2.58M | +29.7% |
| FY2014 | Dec 31, 2014 | $1.99M | +289.1% |
| FY2013 | Dec 31, 2013 | $511.10K | -50.1% |
| FY2012 | Dec 31, 2012 | $1.02M | +4109.4% |
| FY2011 | Dec 31, 2011 | $24.32K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $7.33M | +9.9% |
| Q2 FY2026 | Jun 30, 2026 | $7.05M | +3.4% |
| Q1 FY2026 | Mar 31, 2026 | $6.13M | -1.2% |
| Q4 FY2025 | Dec 31, 2025 | $6.80M | +8.8% |
| Q3 FY2025 | Sep 30, 2025 | $6.67M | +26.8% |
| Q2 FY2025 | Jun 30, 2025 | $6.81M | +4.8% |
| Q1 FY2025 | Mar 31, 2025 | $6.21M | -9.7% |
| Q4 FY2024 | Dec 31, 2024 | $6.26M | +17.8% |
| Q3 FY2024 | Sep 30, 2024 | $5.26M | -6.3% |
| Q2 FY2024 | Jun 30, 2024 | $6.50M | +8.0% |
| Q1 FY2024 | Mar 31, 2024 | $6.87M | +26.0% |
| Q4 FY2023 | Dec 31, 2023 | $5.31M | -7.7% |
| Q3 FY2023 | Sep 30, 2023 | $5.61M | +55.0% |
| Q2 FY2023 | Jun 30, 2023 | $6.02M | +21.7% |
| Q1 FY2023 | Mar 31, 2023 | $5.46M | -14.9% |
| Q4 FY2022 | Dec 31, 2022 | $5.76M | -24.8% |
| Q3 FY2022 | Sep 30, 2022 | $3.62M | -50.4% |
| Q2 FY2022 | Jun 30, 2022 | $4.94M | -46.9% |
| Q1 FY2022 | Mar 31, 2022 | $6.41M | -18.3% |
| Q4 FY2021 | Dec 31, 2021 | $7.66M | -18.8% |
| Q3 FY2021 | Sep 30, 2021 | $7.30M | -4.7% |
| Q2 FY2021 | Jun 30, 2021 | $9.31M | +42.3% |
| Q1 FY2021 | Mar 31, 2021 | $7.85M | +24.1% |
| Q4 FY2020 | Dec 31, 2020 | $9.43M | +76.7% |
| Q3 FY2020 | Sep 30, 2020 | $7.66M | +74.1% |
| Q2 FY2020 | Jun 30, 2020 | $6.55M | +48.8% |
| Q1 FY2020 | Mar 31, 2020 | $6.32M | +83.1% |
| Q4 FY2019 | Dec 31, 2019 | $5.34M | +33.5% |
| Q3 FY2019 | Sep 30, 2019 | $4.40M | +19.2% |
| Q2 FY2019 | Jun 30, 2019 | $4.40M | +10.8% |
| Q1 FY2019 | Mar 31, 2019 | $3.45M | +2.9% |
| Q4 FY2018 | Dec 31, 2018 | $4.00M | +18.2% |
| Q3 FY2018 | Sep 30, 2018 | $3.69M | +59.9% |
| Q2 FY2018 | Jun 30, 2018 | $3.97M | +90.5% |
| Q1 FY2018 | Mar 31, 2018 | $3.36M | +80.6% |
| Q4 FY2017 | Dec 31, 2017 | $3.38M | +89.3% |
| Q3 FY2017 | Sep 30, 2017 | $2.31M | – |
| Q2 FY2017 | Jun 30, 2017 | $2.08M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.86M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.79M | – |
See a number that looks wrong?